Workvivo by Zoom is named preferred migration partner for Workplace from Meta

Meta is discontinuing Workplace and will partner with Workvivo to assist with customer transitions.

SAN JOSE, Calif., May 14, 2024 (GLOBE NEWSWIRE) — Today, Workvivo by Zoom was named Meta’s only preferred migration partner for its customers as it retires Workplace from Meta.

Meta is discontinuing Workplace from Meta – its employee engagement platform. To assist with customer transitions, Meta will partner with Workvivo as its only preferred migration partner.

Workplace from Meta and Workvivo plan to provide migration tools for customers migrating to Workvivo and Workvivo will also offer additional implementation services at no further cost to support customers’ transition.

Workplace from Meta customers can find more information about migrating to Workvivo here.

John Goulding, CEO and founder of Workvivo, said: “We know that the news today may be disruptive for Workplace from Meta customers, but we’re so excited about the opportunity to support and help them. Meta has made a huge impact in this market, and we believe that Workvivo is the natural choice for Workplace from Meta customers to transition their employee experience platform.

“It’s our top priority to support customers through this transition, and our team is working to make this process as frictionless as possible. We put our customers first, and this will be no different for the Workplace from Meta customers. We are excited to welcome Workplace from Meta customers into our incredible customer community and see the amazing things they can do with Workvivo.”

Eric S. Yuan, CEO and founder of Zoom said: “Since Workvivo joined the Zoom family, we’ve seen how powerful this platform is at engaging workforces and bringing culture to life – especially for frontline employees who may not have a desk or even an email address. Workvivo has seen momentous growth as organizations around the world are increasingly prioritizing the employee experience. We are excited to support Workplace from Meta’s customers and help them reach their goals of reaching and engaging employees – whether they’re desk or frontline workers.”

Workvivo by Zoom is the employee experience platform that simplifies communication and increases engagement by empowering employees to be heard and helping everyone feel included, no matter where they work.

Acquired by Zoom in 2023, Workvivo extends the Zoom Workplace platform to offer its customers new ways to keep employees informed, engaged, and connected. Workvivo is working with some of the world’s best-known brands to help them boost employee engagement and bring their culture to life digitally, including Dollar General, the Virgin Group, Bupa, Ryanair, Lululemon and Amazon.

About Workvivo by Zoom

Workvivo is an employee experience platform that simplifies communication and increases engagement by empowering employees to be heard and helping everyone feel included, no matter where they work. The platform unifies employee communications, engagement, intranet, and measurement features into one modern employee app that captures the heartbeat of the organization and brings its culture to life.

Founded in 2017, Workvivo has seen momentous growth, which led to its acquisition by Zoom in 2023. Workvivo powers the employee experience at companies all over the world across all industries, including Amazon, Motherson, White Castle, Bupa and Ryanair. Workvivo regularly tops software review sites, including Gartner Digital, with a #1 spot on G2 for internal communications, intranet and engagement tool categories. For more information, visit www.workvivo.com.

Public Relations
Eleanor O’Mahony
eleanor.omahony@zoom.us

GlobeNewswire Distribution ID 9117415

MedSource Labs Announces Innovation in Safety, Accuracy and Functionality of IV Catheters

MedSource Labs Unveils ClearSafe Comfort® and TrueSafe Comfort® Blood Control Safety IV Catheters to protect medical staff and patients

[Minneapolis, Minnesota, Chanhassen], May 14, 2024 (GLOBE NEWSWIRE) — MedSource Labs moves the needle in the peripheral safety IV market with the announcement of ClearSafe Comfort and TrueSafe Comfort Blood Control IV Catheters with groundbreaking active blood control check valve technology.

ClearSafe Comfort and TrueSafe Comfort Blood Control IV catheters provide significant benefits over other IV catheters.

  1. Safety: A new blood control device to significantly reduce the risk of exposure to bloodborne pathogens to the caregiver and patient.
  2. Precision: A translucent flashback chamber confirms vessel entry and ensures accuracy.
  3. Front-line functionality: The ergonomic design and non-slip grip ensure easy handling for healthcare workers.

 

“Healthcare professionals subject themselves to the risks associated with needlestick injuries and exposure to bloodborne pathogens every time they access a vein,” said Dave Kunelius, President at MedSource Labs. “ClearSafe Comfort and TrueSafe Comfort Blood Control Safety IV Catheters have been engineered to minimize these risks, allowing medical staff to better serve their patients without distraction or worry.”

These devices conform to the U.S. Needlestick Safety and Prevention Act.

MedSource Labs is a leading medical product developer and supplier specializing in high-quality products and innovative medical product development. The ClearSafe Comfort and TrueSafe Comfort Blood Control Safety IV Catheters are part of MedSource Labs’ high-performing IV catheter lines focused on caring for the caregiver. See the TrueSafe Animations and ClearSafe Animations for a detailed view.

“Quality has always been a key component of our IV catheter products, and the ClearSafe Comfort and TrueSafe Comfort blood control products raise the bar for medical staff safety and patient care,” said Kunelius.

MedSource Labs is ISO 13485:2016 certified for quality management in medical device manufacturing, registered with the FDA, and the blood control catheters are 510(k) Cleared Products.

ABOUT MEDSOURCE LABS

MedSource Labs is a leading provider of quality medical products, specializing in high-quality products, equipment and innovative class II medical product development. For over two decades, MedSource Labs has been a trusted provider of quality medical products at a superb value. Recently, MedSource Labs has expanded into new markets and grown its international services and offerings, including a focus on the EMERGE product imagine/design/build process.

Attachment

Jeremy Belloit
MedSource Labs
(952) 472-0131
jbelloit@medsourcelabs.com

GlobeNewswire Distribution ID 9116905

Nyxoah to Release First Quarter 2024 Financial Results on May 14, 2024

Mont-Saint-Guibert, Belgium – May 13, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the first quarter 2024 on Tuesday, May 14, 2024, after market close. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET.

A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah’s Q1 2024 earnings call webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast.

If you plan to ask a question, please use the following link: Nyxoah’s Q1 2024 earnings call. After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call.

The archived webcast will be available for replay shortly after the close of the call.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Forward-looking statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or managements’ current expectations regarding the Genio® system; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; and the Company’s results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2024, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Contacts:
Nyxoah
David DeMartino, Chief Strategy Officer
IR@nyxoah.com

Attachment

GlobeNewswire Distribution ID 1000950583

Unusual Movement in the Price of the Shares of Cordoba Logistics and Ventures Limited

Karachi, Cordoba Logistics and Ventures Limited (CLVL) has responded to a notice from the Pakistan Stock Exchange (PSX) regarding the unusual movement in its share prices. According to information available from the Pakistan Stock Exchange (PSX), the company received the notice on May 9, 2024, in line with Section 97 of the Securities Act, 2015, read with Clause 5.6.3 of the PSX Regulations.

The company reported that the only notable development that occurred over the past few days was a series of share purchases by Mr. Danish Elahi, the Chief Executive Officer and Director of CLVL. These transactions included the purchase of 90,000 shares at a rate of 7.43 on April 29, 310,000 shares at 7.91 on April 30, 40,000 shares at 8.41 on May 2, 250,500 shares at 8.76 on May 3, 5,000 shares at 9.55 on May 6, 16,000 shares at 10.55 on May 7, and 50,000 shares at 11.46 on May 8. All transactions were conducted on the open market.

CLVL also confirmed compliance with Clause 5.6.4 of the PSX Regulations, and stated that no other developments had transpired that might impact the price movement of the company's traded securities. The company has made all relevant information available and remains open to further inquiries on this matter.

HBL Growth Fund Reports Strong Performance in First Four Months of 2024

Karachi, According to information available from the Pakistan Stock Exchange (PSX), the HBL Growth Fund - (A) NC has reported a robust earnings per share (EPS) of Rs. 9.45 for January to April 2024. The fund's today's rate stood at Rs. 7.18, with a daily weighted average rate of Rs. 12%. The fund, which was listed in 1980, has a paid-up capital of Rs. 378.2 million. It previously declared a 12% distribution for its shareholders. The market lot for the fund is 10 shares.

Buxly Paints Limited Struggles to Declare Dividends Despite Active Trading

Karachi, Buxly Paints Limited (BUXL) traded with a volume of 490,315 shares, peaking at Rs. 113 and closing at Rs. 95.49.

According to information available from the Pakistan Stock Exchange (PSX), Buxly Paints has not issued any dividends recently, indicating potential challenges in the paints and coatings market. The company, which has been a part of the stock exchange since 1986, reported an earnings per share of Rs. 1.89 for the first four months of 2024.

Tri-Star Mutual Fund NC Struggles with Negative Earnings

Karachi, According to information available from the Pakistan Stock Exchange (PSX), Tri-Star Mutual Fund NC has experienced a challenging period with an EPS of -Rs. 3.26 from January to April 2024. The mutual fund's rate today is Rs. 4.41, with no distributions reported. The fund, which started in 1994, has a paid-up capital of Rs. 2.52 million and a market lot of 10 shares.

Colgate-Palmolive (Pakistan) Enjoys Exceptional Dividend Payouts and High Share Value

Karachi, Colgate-Palmolive (Pakistan) (COLG) experienced trading with 483,173 shares, reaching a high of Rs. 1640 and closing at a striking rate of Rs. 1301.06.

According to information available from the Pakistan Stock Exchange (PSX), Colgate-Palmolive has been very generous with its dividends, offering a 525% dividend and a 15% bonus in 2022, and an even more impressive 650% dividend and a 145% bonus in 2023, along with a 225% interim dividend for 2024. The company has been an established presence in the market since 1984, and it reported a remarkable earnings per share of Rs. 42.88 for January to April 2024.

B.F. Modaraba Reports Negative Earnings Amid Declining Trade

Karachi, According to information available from the Pakistan Stock Exchange (PSX), B.F. Modaraba, represented by the symbol BFMOD, experienced a trading volume of 33,000 shares. The company reported a negative EPS of -0.80 for the period from January to April 2024. Listed in 1989, B.F. Modaraba has a paid-up capital of Rs. 10 million. No distributions were declared for the current or previous year, and the market lot size remains at 10 shares.

Data Agro Ltd Reports Modest Earnings with No Dividend Declarations

Karachi, Data Agro Ltd, trading under the symbol DAAG, reported modest earnings with an earnings per share of 4.21 for January to April 2024, according to the Pakistan Stock Exchange (PSX). The company did not declare any dividends for 2022 or 2023. The trading volume was relatively low at 111,500 shares. Data Agro has been listed since 1994 and operates with a market lot size of 10 shares and a paid-up capital of Rs. 10 million.

Constellation Modaraba 1st Reports No Earnings; Trading Inactive

Karachi, According to information available from the Pakistan Stock Exchange (PSX), Constellation Modaraba 1st, under the symbol FCONM, reported no earnings for the period from January to April 2024, with no shares traded. The company, listed in 1991, has a paid-up capital of Rs. 10 million and a market lot size of 10 shares. No distributions were declared for the year.

Descon Oxychem Ltd. Shows Solid Earnings and Rising Dividend Payouts

Karachi, Descon Oxychem Ltd., symbolized by DOL, demonstrated solid financial performance with an earnings per share of 8.00 for January to April 2024. According to the Pakistan Stock Exchange (PSX), the company declared a 20% dividend for 2022 and increased it to 40% for 2023. The trading volume was substantial at 43,526,000 shares. Descon Oxychem has been listed since 2008 and maintains a market lot size of 10 shares with a paid-up capital of Rs. 10 million.